Alcidion Group Limited (AU:ALC)
ASX:ALC
Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume609.88K
Average Volume (3M)796.98K
Market Cap
AU$147.79M
Enterprise ValueAU$131.49M
Total Cash (Recent Filing)AU$14.20M
Total Debt (Recent Filing)AU$1.32M
Price to Earnings (P/E)36.4
Beta0.93
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,343,558,700
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside47.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$47.55M
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn 88%+ gross margin reflects a software-centric cost structure with low incremental delivery costs. This scalability lets revenue growth translate to durable gross profit, supporting investment in product development and customer success without large increases in cost of goods sold.
Sustained Revenue GrowthRevenue growth near 36% indicates sustained demand for clinical software and healthy contract momentum. For a recurring-license/subscription model this growth suggests expanding footprint in hospital systems and durable contract renewals that can compound revenue over multiple years.
Strong Cash Generation & Low LeverageVery large FCF improvement and near-par FCF-to-net income show effective cash conversion from operations. Combined with negligible debt, the company has financial flexibility to fund implementations, R&D, or acquisitions without material refinancing risk, a durable balance-sheet strength.
Bears Say
Negative Operating Profitability (EBIT)A negative EBIT margin shows operating costs still outpace core earnings despite high gross margins. Unless operating expenses are reined in or revenue scales faster, structural operating losses can limit reinvestment capacity and make profitability recovery dependent on sustained top-line expansion.
Low Net Profit MarginA ~4% net margin implies limited retained earnings from sales after all costs. For a software firm this constrains free cash generation durability if margins don't expand, and reduces cushion against slower revenue periods or large implementation projects that can temporarily depress earnings.
Modest Return On EquityROE under 2% signals that shareholder capital is not yet generating strong returns. Even with low leverage, modest ROE highlights inefficiencies or heavy reinvestment that may delay shareholder value creation unless margins and operating leverage improve over the medium term.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$147.79M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 85 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Feb 25, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is 0.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,343,558,700 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.15 (47.50% Upside)
AU$0.15 (47.50% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
4.37%
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(47.50% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Singular Health Group Ltd
―
PainChek Ltd
―
Options Prices
Currently, No data available
---